15,023 Shares in Neuronetics, Inc. $STIM Bought by R Squared Ltd

R Squared Ltd bought a new position in Neuronetics, Inc. (NASDAQ:STIM) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 15,023 shares of the company’s stock, valued at approximately $52,000.

A number of other large investors also recently added to or reduced their stakes in STIM. Larson Financial Group LLC purchased a new position in Neuronetics in the 1st quarter worth $25,000. FORA Capital LLC purchased a new position in Neuronetics in the 1st quarter worth $42,000. National Bank of Canada FI raised its position in Neuronetics by 19,491.5% in the 1st quarter. National Bank of Canada FI now owns 11,559 shares of the company’s stock worth $42,000 after purchasing an additional 11,500 shares during the period. Fermata Advisors LLC purchased a new position in Neuronetics in the 2nd quarter worth $52,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Neuronetics in the 1st quarter worth $55,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a report on Saturday. Canaccord Genuity Group cut their price target on shares of Neuronetics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.00.

Neuronetics Trading Up 5.4%

Shares of STIM opened at $3.12 on Monday. The firm’s 50-day moving average price is $3.04 and its 200-day moving average price is $3.63. The firm has a market capitalization of $206.29 million, a price-to-earnings ratio of -2.76 and a beta of 1.17. The company has a current ratio of 2.02, a quick ratio of 1.84 and a debt-to-equity ratio of 1.76. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.92.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). The company had revenue of $38.11 million for the quarter, compared to the consensus estimate of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Neuronetics, Inc. will post -1.13 EPS for the current year.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.